BioIVT’s Promega Service Provider Technologies
BioIVT will now offer Promega Immune Checkpoint and antibody-dependent cell-mediated cytotoxicity (ADCC) Reporter Bioassays to support immunology and immuno-oncology research. This offering complements BioIVT’s custom assay development services using client-provided cells and reagents.
At BioIVT, our PHASEZERO® Research Team, leaders in high quality human tissue-based research solutions supporting drug discovery and development in our HTA-licensed facility, continue to expand our strong immuno-oncology portfolio for drug development and validation of immune checkpoint targets and characterization of novel therapeutics. Development and validation of immuno-oncology (IO) targets requires an understanding of the complex biology occurring in the immune system and in the tumor, which BioIVT now supports through the following services:
- Multiplex immunohistochemistry and digital pathology to visualize the spatial relationship and functional state of immune cell types with tumor cells, defining the location within the tumor microenvironment (TME)
- Assessment of the off-target binding (GLP-tissue cross reactivity) of novel therapeutic antibodies and antibody-like molecules and
- NEW - Measurement of Fc effector function, potency and stability of novel therapeutics
BioIVT has now extended their services capabilities to support scientists in screening novel therapeutics by offering a range of robust Promega Bioassays, including measurement of immune checkpoint activity and ADCC.
In this example of the Promega ADCC Reporter Bioassay, V Variant (Mfg #G7015, Promega, Madison, WI, USA), the therapeutic test antibodies included Rituximab (Rituxan) (Mfg #10F381, Novus Bio, Centennial CO, USA) and Obinutuzumab (Mfg #hcd20ga-mab13, Gazyva / Gazyvaro) (San Diego, CA, USA).
As expected, Obinutuzumab resulted in a greater RLU over that seen with Rituximab. Obinutuzumab, a second-generation type II non-fucosylated, fully humanized IgG1 monoclonal antibody (mAb), has demonstrated enhanced ADCC activity over first-generation standard monoclonal antibodies such as Rituximab.
In this example of the Promega Immune Checkpoint Bioassays (Mfg #J1250, Promega, Madison, WI, USA), for characterizing immune-modulating antibodies, the therapeutic test biologicals included Keytruda® (Pembrolizumab, Merck), OPDIVO® (Nivolumab, Bristol-Meyer Squibb) and PD-1/PD-L1 inhibitor 3, a large macrocyclic inhibitor.
As expected, each therapeutic antibody was able to release the PD-1/PD-L1 inhibition of TCR signaling to induce NFAT-mediated luciferase activity.